Payers’ Use Of Real-World Evidence For Drug Coverage On The Rise – IMS Health
A new study by IMS Health shows payers globally are making more drug reimbursement decisions based on real-world evidence – including 25% of more than 100 identified case studies using biopharma industry-generated data.
You may also be interested in...
Manufacturers, payers and providers will need to learn how to trust each other’s data sources if the benefits of the big datasets of real-world evidence are to be realized, pharmaceutical execs say.
Pharmaceutical companies are beginning to leverage big data to become more integrated into health care delivery, looking to care coordination and other “services adjacent to medicines,” IBM’s John Piccone reports.
COPD stalwarts Symbicort and Seretide never have been compared head-to-head in the clinic but Swedish researchers now have analyzed the pair’s respective association with pneumonia, using Sweden’s modern infrastructure and national databases. The review concluded that the AstraZeneca compound soundly beats GlaxoSmithKline’s, based on real-world evidence.